Compound ID | 151
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against multidrug resistant Gram-negative infections |
| Propensity to select resistant mutants: | No (demonstrated high resistance) |
| Description: | A siderophore-sulfactam |
| Institute where first reported: | Basilea Pharmaceutica, Switzerland |
| Year first mentioned: | 2008 |
| Highest developmental phase: | Phase 1 |
| Development status: | Discontinued |
| Reason Dropped: | Liver injury detected 3-days post treatment (iv formulation); preclinical studies of inhalation also terminated due to 'lack of confidence in candidate's success' |
| Chemical structure(s): | |||||||||||
|
|